相关实验视频
Updated: Jun 28, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
聚乙醇抑制铁和调节液体-液体相分离,以减轻阿尔茨海默病的发生
Hariharan Moorthy1, Madhu Ramesh1, Dikshaa Padhi1
1Bioorganic Chemistry Laboratory, New Chemistry Unit and School of Advanced Materials, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, Karnataka 560064, India. tgraju@jncasr.ac.in.
Materials horizons
|April 22, 2024
概括
新的多甲基醇剂,PDP和PLDP,通过抑制铁和粉样毒性来对抗阿尔茨海默病. PLDP独特地调节液-液相分离,为神经退行性疾病提供了一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 聚合物科学 聚合物科学
背景情况:
- 阿尔茨海默病 (AD) 涉及复杂的神经退行,影响认知.
- 目前针对粉样蛋白-β (Aβ) 和病理的治疗方法的疗效有限.
- 铁和液液相分离 (LLPS) 是AD病变发生的新兴机制.
研究的目的:
- 调查多种甲基 (PDP,PLDP) 作为对抗AD的多功能剂.
- 探索它们在调节铁和粉样毒性之间的相互作用方面的潜力.
- 评估它们对tau LLPS和聚合物形成的影响.
主要方法:
- 聚乙醇 (PDP,PLDP) 的合成和表征.
- 在体外测试中测试了性铁池 (LIP) 封存,Aβ和tau聚合抑制.
- 自由基清除和线粒体保护试验.
- 铁灭抑制和神经元细胞死亡救援的评估.
- 分析PLDP对tau LLPS和聚合模块化的影响.
主要成果:
- 聚乙醇封存LIP,抑制Aβ和tau聚合,清除激素,并保护线粒体.
- PDP和PLDP有效地预防铁亡,并从死亡中拯救神经元细胞.
- PLDP独特地促进tau LLPS,同时抑制有毒聚合物的形成.
- 这代表了一种基于聚合物的新策略,结合了铁灭抑制和粉样蛋白毒性对抗.
结论:
- 聚乙醇显示出作为阿尔茨海默病多功能治疗剂的巨大潜力.
- 对铁和粉样蛋白病理的双重作用,加上tau LLPS调制,提供了一个全面的方法.
- PLDP的独特机制为在AD更广泛的背景下针对陶病症提供了一个新的策略.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K

